- Home
- NVCR vs TNGX Comparison
NVCR vs TNGX Comparison
Compare NVCR & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVCR
- TNGX
- Stock Information
- Founded
- NVCR 2000
- TNGX 2014
- Country
- NVCR Switzerland
- TNGX United States
- Employees
- NVCR N/A
- TNGX N/A
- Industry
- NVCR Medical/Dental Instruments
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- NVCR Health Care
- TNGX Health Care
- Exchange
- NVCR Nasdaq
- TNGX Nasdaq
- Market Cap
- NVCR 1.3B
- TNGX 1.0B
- IPO Year
- NVCR 2015
- TNGX N/A
- Fundamental
- Price
- NVCR $11.25
- TNGX $7.87
- Analyst Decision
- NVCR Buy
- TNGX Strong Buy
- Analyst Count
- NVCR 7
- TNGX 6
- Target Price
- NVCR $28.64
- TNGX $10.80
- AVG Volume (30 Days)
- NVCR 1.5M
- TNGX 4.5M
- Earning Date
- NVCR 10-30-2025
- TNGX 11-04-2025
- Dividend Yield
- NVCR N/A
- TNGX N/A
- EPS Growth
- NVCR N/A
- TNGX N/A
- EPS
- NVCR N/A
- TNGX N/A
- Revenue
- NVCR $642,269,000.00
- TNGX $66,501,000.00
- Revenue This Year
- NVCR $9.54
- TNGX $20.41
- Revenue Next Year
- NVCR $5.70
- TNGX N/A
- P/E Ratio
- NVCR N/A
- TNGX N/A
- Revenue Growth
- NVCR 11.17
- TNGX 53.29
- 52 Week Low
- NVCR $10.70
- TNGX $1.03
- 52 Week High
- NVCR $34.13
- TNGX $9.70
- Technical
- Relative Strength Index (RSI)
- NVCR 35.05
- TNGX 49.06
- Support Level
- NVCR $10.70
- TNGX $7.49
- Resistance Level
- NVCR $12.01
- TNGX $8.35
- Average True Range (ATR)
- NVCR 0.57
- TNGX 0.64
- MACD
- NVCR -0.11
- TNGX -0.03
- Stochastic Oscillator
- NVCR 15.48
- TNGX 37.59
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.